Combining the specific anti-MUC1 antibody TAB004 and LIP-MSA-IL-2 limits pancreatic cancer progression in immune competent murine models of pancreatic ductal adenocarcinoma
Name
fonc-09-00330.pdf
Description
Published version
Size
4 MB
Format
Adobe PDF
Checksum (MD5)
46d1a07e5c4a05d35235bb277951b45c
Author(s)
Dreau, Didier
Moore, Laura Jeffords
Wu, Mike
Roy, Lopa Das
Dillion, Lloye
Porter, Travis
Puri, Rahul
Momin, Noor
Wittrup, Karl Dane
Mukherjee, Pinku
Date Issued
April 2019
Journal
Frontiers in Oncology
Publisher
Frontiers Media SA
Citation
Dréau, Didier, Laura Jeffords Moore, Mike Wu et al. "Combining the specific anti-MUC1 antibody TAB004 and LIP-MSA-IL-2 limits pancreatic cancer progression in immune competent murine models of pancreatic ductal adenocarcinoma" Frontiers of Oncology, 9,330 (April 2019): p.1-15. Copyright © 2019 Dréau, Moore, Wu, Roy, Dillion, Porter, Puri, Momin, Wittrup and Mukherjee.
Version
Final published version
Abstract
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Immunotherapy regimens have shown success in subsets of cancer patients; however, their efficacy against pancreatic ductal adenocarcinoma (PDA) remain unclear. Previously, we demonstrated the potential of TAB004, a monoclonal antibody targeting the unique tumor-associated form of MUC1 (tMUC1) in the early detection of PDA. In this study, we evaluated the therapeutic benefit of combining the TAB004 antibody with Liposomal-MSA-IL-2 in immune competent and human MUC1 transgenic (MUC1.Tg) mouse models of PDA and investigated the associated immune responses. Treatment with TAB004 + Lip-MSA-IL-2 resulted in significantly improved survival and slower tumor growth compared to controls in MUC1.Tg mice bearing an orthotopic PDA.MUC1 tumor. Similarly, in the spontaneous model of PDA that expresses human MUC1, the combination treatment stalled the progression of pancreatic intraepithelial pre-neoplastic (PanIN) lesion to adenocarcinoma. Treatment with the combination elicited a robust systemic and tumor-specific immune response with (a) increased percentages of systemic and tumor infiltrated CD45+CD11b+ cells, (b) increased levels of myeloperoxidase (MPO), (c) increased antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP), (d) decreased percentage of immune regulatory cells (CD8+CD69+ cells), and (e) reduced circulating levels of immunosuppressive tMUC1. We report that treatment with a novel antibody against tMUC1 in combination with a unique formulation of IL-2 can improve survival and lead to stable disease in appropriate models of PDA by reducing tumor-induced immune regulation and promoting recruitment of CD45+CD11b+ cells, thereby enhancing ADCC/ADCP. Keywords: ADCC, Antibody, IL-2, Immunocompetent, Immunotherapy, MUC1, PDA, TAB004
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3389/fonc.2019.00330
